Funda Meric-Bernstam, MD, discusses the outcomes of the FONTANA trial of an investigational folate receptor alpha–targeting antibody-drug conjugate in platinum-resistant ovarian cancer.
Funda Meric-Bernstam, MD
Advertisement
Articles by Funda Meric-Bernstam, MD
Funda Meric-Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily pretreated locally advanced or metastatic urothelial cancer.
Funda Meric-Bernstam, MD, discusses the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-expressing solid tumors.
Funda Meric-Bernstam, MD, discusses fam-trastuzumab deruxtecan-nxki and the evaluation of the agent in the phase 2 DESTINY-PanTumor02 trial.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Talazoparib/Enzalutamide in HRR-Mutated Prostate Cancer
2
ADCs Shine, Mixed Bag for Immunotherapy at ESMO 2026 Presidential Symposium III
3
ESMO 2026: Survival Gains and New Treatment Strategies in GI Cancers
4
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
5